News Roche hails 4 year NICE access deal for Gazyvaro NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the dru
News Ultragenyx to slash costs after Angelman trial failure Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
